Christa Firbas

Research Associate
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Wien, Austria

Presentation(s):

• OC 73.3 - VGA039, a Protein S-targeting monoclonal antibody, demonstrates in a Phase Ia healthy volunteer trial the potential of subcutaneous weekly or less frequent prophylactic dosing for bleeding disorders

  Wednesday, June 26, 2024
  10:45 – 11:00 ICT